Literature DB >> 25155838

A systematic review of patient preference elicitation methods in the treatment of colorectal cancer.

A Currie1, A Askari, S Nachiappan, N Sevdalis, O Faiz, R Kennedy.   

Abstract

AIM: This systematic review aimed to assess the use of patient preference in colorectal cancer treatment. Eliciting patient preference is important for shared decision-making in colorectal cancer treatment. The introduction of newer treatments, which balance quality of life and overall survival, makes this an important future focus.
METHOD: A systematic search strategy of MEDLINE, Embase, PsycINFO, CINAHL and the Cochrane Database for Systematic Reviews was undertaken to obtain relevant articles. Information regarding the type of patients included, preference instruments, study settings, outcomes and limitations was extracted.
RESULTS: The eight articles comprising this review each described an empirical study using a validated instrument to define patient preference for an aspect of colorectal cancer treatment. The evidence suggests that patients are prepared to trade significant reductions in life expectancy to avoid certain complications of colorectal surgery, particularly stoma formation. In the adjuvant setting, patients are prepared to risk significant treatment side effects to gain small potential increases in life expectancy and chance of survival. Where neoadjuvant or adjuvant treatment risks worsening function, however, patients generally forgo any potential increase in survival to improve bowel function and therefore quality of life. The only predictors of preference were tertiary education and previous cancer treatment.
CONCLUSION: Most patients judge a moderate survival benefit to be sufficient to make adjuvant therapy for colorectal cancer worthwhile, but they are willing to trade a potential reduction in life expectancy and survival to avoid certain unwanted surgical sequelae. Colorectal Disease
© 2014 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  Patient preference; colorectal cancer; decision-making; oncology; surgery

Mesh:

Year:  2015        PMID: 25155838     DOI: 10.1111/codi.12754

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  7 in total

Review 1.  Targeted therapy in first line treatment of RAS wild type colorectal cancer.

Authors:  Vincenzo Formica; Mario Roselli
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

Review 2.  Methods to Summarize Discrete-Choice Experiments in a Systematic Review: A Scoping Review.

Authors:  Daksh Choudhary; Megan Thomas; Kevin Pacheco-Barrios; Yuan Zhang; Pablo Alonso-Coello; Holger Schünemann; Glen Hazlewood
Journal:  Patient       Date:  2022-07-13       Impact factor: 3.481

3.  Patient experience, satisfaction and shared decision-making in colorectal cancer screening: protocol of the mixed-methods study CyDESA.

Authors:  Anna Selva; Pilar López; Teresa Puig; Francesc Macià; Clara Selva; Yolanda Álvarez-Pérez; Rebeca Terraza; Andrea Burón; Salvador Tarek Machlab; Carles Pericay; Ivan Solà; Núria Torà; Vanesa Rodríguez; Cristina Barrufet; Anna Aymar; Marisa Baré
Journal:  BMJ Open       Date:  2022-05-30       Impact factor: 3.006

4.  Methods to perform systematic reviews of patient preferences: a literature survey.

Authors:  Tsung Yu; Nomin Enkh-Amgalan; Ganchimeg Zorigt
Journal:  BMC Med Res Methodol       Date:  2017-12-11       Impact factor: 4.615

5.  Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment.

Authors:  Juan Marcos González; Sarika Ogale; Robert Morlock; Joshua Posner; Brett Hauber; Nicolas Sommer; Axel Grothey
Journal:  Cancer Manag Res       Date:  2017-04-27       Impact factor: 3.989

Review 6.  Methods to Assess Patient Preferences in Old Age Pharmacotherapy - A Systematic Review.

Authors:  Annette Eidam; Anja Roth; André Lacroix; Sabine Goisser; Hanna M Seidling; Walter E Haefeli; Jürgen M Bauer
Journal:  Patient Prefer Adherence       Date:  2020-03-04       Impact factor: 2.711

7.  Epigallocatechin gallate inhibits dimethylhydrazine-induced colorectal cancer in rats.

Authors:  Yu Wang; Hei-Ying Jin; Ming-Zhi Fang; Xiao-Feng Wang; Hao Chen; Shu-Liang Huang; De-Song Kong; Min Li; Xiu Zhang; Yu Sun; Shui-Ming Wang
Journal:  World J Gastroenterol       Date:  2020-05-07       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.